Cantor Fitzgerald raises target for Pfizer stock to USD 28.00

Published on 10/09/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer reported USD 15.00 billion revenue and USD 0.77 adjusted EPS in Q2 2026. Pfizer stock costs EUR 25.13 on October 9, 2026 after EUR 24.79.

Key points in brief

Pfizer's latest analyst target rose from USD 27.00 to USD 28.00 on October 9, 2026.
Second-quarter 2026 revenue reached USD 15.00 billion and adjusted diluted earnings per share was USD 0.77.
The Lang & Schwarz price was EUR 25.13 on October 9, 2026, up 1.37 percent versus EUR 24.79.
Pfizer's next earnings date is November 3, 2026, while Italy talks are scheduled for November 10, 2026.

Sanfte Aquarell-Illustration einer Bürotürme-Skyline, Symbolbild für Pfizer Inc. Hauptsitz — Aquarellmalerei der New Yorker Skyline repräsentiert den Firmensitz von Pfizer Inc., ISIN US7170811035, Pharma-Branche, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) received a higher USD 28.00 price target from Cantor Fitzgerald on October 9, 2026, up from USD 27.00, while the firm kept its Neutral rating. Pfizer stock was trading at EUR 25.13 at Lang & Schwarz at 4:02 p.m. CEST on October 9, 2026, up 1.37 percent versus the prior close of EUR 24.79.

The target moves to USD 28.00

According to 24/7 Wall St. on October 9, 2026, Cantor Fitzgerald raised its Pfizer target from USD 27.00 to USD 28.00 and retained Neutral. The target sits alongside a USD 29.03 consensus target cited in the same market coverage, leaving Pfizer's analyst picture more cautious than the higher target alone suggests.

Pfizer's second-quarter 2026 revenue was USD 15.00 billion, an operational increase of 1 percent from the prior year, while adjusted diluted earnings per share reached USD 0.77. Yahoo Finance published the earnings-call transcript dated August 4, 2026, which also said Pfizer raised its full-year 2026 revenue guidance midpoint by USD 500 million to a range of USD 60.50 billion to USD 62.50 billion.

Three milestones shaped the setup

On August 4, 2026, Pfizer reported USD 15.00 billion of second-quarter revenue and USD 0.77 adjusted diluted earnings per share, according to Yahoo Finance. On October 7, 2026, Reuters reported that unions said Pfizer planned to cut 330 jobs at its Sicily plant, which employs 550 people. On October 9, 2026, Cantor Fitzgerald raised its target from USD 27.00 to USD 28.00, as reported by 24/7 Wall St.

What does the target mean for Pfizer?

The immediate signal is measured rather than aggressive: Cantor's Neutral rating accompanied the USD 28.00 target, while Pfizer's second-quarter adjusted diluted earnings per share exceeded management's expectation. The operating comparison is also important because revenue grew 1 percent operationally year over year, with non-COVID products delivering the stronger contribution described on the earnings call.

The next dates are October and November

Two dates now frame the next company developments. The Italian industry minister is scheduled to visit Pfizer's Sicily plant on October 23, 2026, and Pfizer's next earnings report is scheduled for November 3, 2026, according to TradingView; further talks over the Italian plant are scheduled for November 10, 2026, Reuters reported.

Pfizer stock trades higher in Europe

Pfizer's primary listing is the NYSE, where the stock was last at USD 28.09 on October 9, 2026 at 10:06 a.m. ET. Its market capitalization was USD 160.1 billion on October 9, 2026, while the Lang & Schwarz euro quote stood at EUR 25.13 at 4:02 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.